• BridgeBio Pharma approved restricted stock units covering 57,853 common shares for 32 new employees on October 14, 2026.
• Each award will vest 25% on November 16, 2027, followed by quarterly vesting of one-twelfth of the remaining shares.
• Vesting is subject to continued employment with the company or one of its subsidiaries on each vesting date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610160730PRIMZONEFULLFEED9846824) on October 16, 2026, and is solely responsible for the information contained therein.